These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 27449671)

  • 1. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.
    Marconi VC; Grandits G; Okulicz JF; Wortmann G; Ganesan A; Crum-Cianflone N; Polis M; Landrum M; Dolan MJ; Ahuja SK; Agan B; Kulkarni H;
    PLoS One; 2011; 6(5):e17956. PubMed ID: 21625477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART.
    Taiwo BO; Li X; Palella F; Jacobson LP; Margolick JB; Detels R; Rinaldo CR; Phair JP
    HIV Med; 2009 Nov; 10(10):657-60. PubMed ID: 19601997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy.
    Minidis NM; Mesner O; Agan BK; Okulicz JF
    J Int AIDS Soc; 2014; 17(1):18799. PubMed ID: 24499779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained HIV viral suppression following treatment interruption: an observational study.
    Bedimo R; Chen RY; Westfall AO; Raper JL; Allison JJ; Saag MS
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):40-4. PubMed ID: 16438644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil.
    Joao EC; Gouvêa MI; Menezes JA; Sidi LC; Cruz ML; Berardo PT; Ceci L; Cardoso CA; Teixeira Mde L; Calvet GA; Matos HJ
    Int J STD AIDS; 2012 Jan; 23(1):44-7. PubMed ID: 22362687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.
    Neilan AM; Karalius B; Patel K; Van Dyke RB; Abzug MJ; Agwu AL; Williams PL; Purswani M; Kacanek D; Oleske JM; Burchett SK; Wiznia A; Chernoff M; Seage GR; Ciaranello AL;
    JAMA Pediatr; 2017 May; 171(5):450-460. PubMed ID: 28346597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunologic outcomes of HAART-treated HIV-infected women in resource constrain settings: the Belgrade Study.
    Dragović G; Salemović D; Ranin J; Nikolić J; Kušić J; Jevtović D
    Women Health; 2014; 54(1):35-47. PubMed ID: 24555810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.
    Tan R; Westfall AO; Willig JH; Mugavero MJ; Saag MS; Kaslow RA; Kempf MC
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):553-8. PubMed ID: 18285713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological status and virological suppression among HIV-infected adults on highly active antiretroviral therapy.
    Melku M; Abebe G; Teketel A; Asrie F; Yalew A; Biadgo B; Kassa E; Damtie D; Anlay DZ
    Environ Health Prev Med; 2020 Aug; 25(1):43. PubMed ID: 32838734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).
    Oyomopito R; Lee MP; Phanuphak P; Lim PL; Ditangco R; Zhou J; Sirisanthana T; Chen YM; Pujari S; Kumarasamy N; Sungkanuparph S; Lee CK; Kamarulzaman A; Oka S; Zhang FJ; Mean CV; Merati T; Tau G; Smith J; Li PC;
    HIV Med; 2010 Sep; 11(8):519-29. PubMed ID: 20345881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life.
    Gill CJ; Griffith JL; Jacobson D; Skinner S; Gorbach SL; Wilson IB
    J Acquir Immune Defic Syndr; 2002 Aug; 30(5):485-92. PubMed ID: 12154339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse and resilience in relation to HAART medication adherence and HIV viral load among women with HIV in the United States.
    Dale S; Cohen M; Weber K; Cruise R; Kelso G; Brody L
    AIDS Patient Care STDS; 2014 Mar; 28(3):136-43. PubMed ID: 24568654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment.
    Ironson G; O'Cleirigh C; Fletcher MA; Laurenceau JP; Balbin E; Klimas N; Schneiderman N; Solomon G
    Psychosom Med; 2005; 67(6):1013-21. PubMed ID: 16314608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
    Rutstein RM; Gebo KA; Flynn PM; Fleishman JA; Sharp VL; Siberry GK; Spector SA
    Med Care; 2005 Sep; 43(9 Suppl):III15-22. PubMed ID: 16116305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.